Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment

Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients in the third or later line setting. After CAR-T failure, survival outcomes are heterogeneous and a prognostic model in this patient populat...

Descripción completa

Detalles Bibliográficos
Autores: Iacoboni, Gloria, Navarro, Víctor, Sesques, Pierre, Rejeski, Kai, Bastos Oreiro, Mariana, Serpenti, Fabio, Martin Lopez, Ana Africa, Iraola Truchuelo, Josu, Delgado, Javier, Perez, Ariadna, Guerreiro, Manuel, Caballero, Ana Carolina, Martínez Cibrian, Nuria, Luzardo Henriquez, Hugo, Sanchez Pina, Jose Maria, Sancho, Juan Manuel, Ghesquieres, Hervé, Mussetti, Alberto, Lopez Corral, Lucia, Hernani, Rafael, Reguera, Juan Luís, Sureda, Anna, Bosch, Francesc, Martin Garcia-Sancho, Alejandro, Kwon, Mi, Subklewe, Marion, Kuhnl, Andrea, Bachy, Emmanuel, Barba, Pere, Villacampa, Guillermo, Abrisqueta, Pau
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/217361
Acceso en línea:https://hdl.handle.net/2445/217361
Access Level:acceso abierto
Palabra clave:Limfomes
Cèl·lules B
Lymphomas
B cells
Descripción
Sumario:Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients in the third or later line setting. After CAR-T failure, survival outcomes are heterogeneous and a prognostic model in this patient population is lacking. A training cohort of 216 patients with progressive disease (PD) after CAR-T from 12 Spanish centers was used to develop the Post-CAR Prognostic Index (PC-PI); primary endpoint was overall survival (OS) from CAR-T progression. Validation was performed in an external cohort from three different European centers (n = 204). The prognostic score incorporated five variables, assessed at time of PD to CAR-T: ECOG (> 0), hemoglobin (< 10 g/dL), LDH (>= 2xULN), number of extranodal sites (> 1) and time from CAR-T to PD (< 4 months). Patients were classified in four risk groups with distinct OS (p-value < 0.05 in all comparisons). In the validation cohort, median OS in the low (31%), intermediate-low (26%), intermediate-high (17%) and high risk (26%) were 15.7, 7.1, 1.8 and 1.0 months, respectively (p < 0.05 in all comparisons). Results were consistent following adjustment for subsequent treatment. In the external cohort, the PC-PI showed a C-statistic of 0.79 (95%CI 0.76-0.82), outperforming IPI and R-IPI. In conclusion, the PC-PI score is a novel tool for OS prediction and could facilitate risk-adapted management of LBCL patients relapsing after CAR T-cells. Additionally, these results will help stratification and interpretation of trials and real-world data incorporating CART-exposed patients.

Similares en LA Referencia